Thousands of Leading Interventional Cardiologists Witness New Paradigm Shift in Cardiology Procedures
NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc., announced it successfully treated extremely
challenging cases at EuroPCR 2007 in Barcelona, Spain to demonstrate how
the firm’s Side-Branch Stent will ultimately reshape the treatment of
bifurcated lesions. EuroPCR provided an important informational venue
that enabled thousands of interventional cardiologists to review how
Tryton Medical’s first-in-class device, the Side-Branch Stent, will
provide a new standard of care for bifurcated lesions. Approximately
540,000 annual procedures are performed to address bifurcation lesions,
accounting for 20% of all coronary lesions treated. With the exception
of Tryton’s stent, no dedicated solution exists today that fully
addresses these lesions.
The cases, transmitted via satellite to Barcelona, were performed by
members of the Thoraxcenter, Erasmus Medical Center, Rotterdam,
Netherlands, including Dr. George Sianos, Dr. Robert van Geuns, and
Professor Patrick W. J. C. Serruys, M.D., Ph.D. The first case
demonstrated how patients with complex bifurcated lesions can be
definitively treated in scenarios where provisional stenting is
impractical. “This technology has the capacity to redefine the treatment
of bifurcation lesions and resolve a frequent dilemma of the
interventional cardiologist,” said Professor Patrick W. J. C. Serruys,
M.D., Head of the Department of Interventional Cardiology, Thoraxcenter,
Erasmus Medical Center, Rotterdam, Netherlands.
The second case demonstrated the versatility of the “treat the side
branch first” approach in a lesion located far down the right coronary
artery. The side branch, which was at risk of eminent closure, was
stabilized with Tryon’s stent, after which the main vessel was treated
with a superb angiographic result. “Unlike other stents and techniques
used to treat bifurcation lesions, Tryton’s stent is easy to deliver as
it uses standard equipment and techniques compatible with 5 and 6 French
guiding catheters,” said Dr. George Sianos, Senior Interventionalist,
Thoraxcenter, Erasmus Medical Center.
The third case illustrated the use of Tryton’s stent in an extremely
tortuous and calcified artery securing the side branch, after which a
workhorse stent was delivered to the main vessel yielding a beautiful
result. Intravascular ultrasound, performed at the end of each case,
demonstrated complete coverage of the side branch origin. “Tryton’s
device has greatly facilitated the treatment of these patients.
Interventional cardiologists who use Tryton’s stent will no longer have
to worry about the bifurcation as they’ll know the side branch will stay
open and the interventionalist is then free to focus on the treatment of
the main vessel using their the stent of their choice,” said Dr. Sianos.
“Tryton continues to demonstrate impressive results and growth as it
becomes clear that our stent will eventually provide a new standard of
care, thereby enabling any interventional cardiologists to treat the
entire spectrum of bifurcation lesions they encounter every day,” said
H. Richard Davis, CTO, Tryton Medical, Inc. “The benefits of our
Side-Branch Stent have been witnessed by thousands of interventional
cardiologists in Asia, Europe and America. Interventional cardiologists
can quickly grasp how to use our stent to treat complex lesions.
Tryton’s dedicated save-the-side branch approach, allows for securing
the side-branch first, after which the main vessel is treated by the
physician’s main stent of choice, in a predictable manner. These
benefits simply are not offered with provisional stenting,” Davis added.
About Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are
designed to definitively treat bifurcation lesions. 540,000 bifurcation
coronary lesions are sub-optimally treated every year with a variety of
time consuming and technically challenging procedures. No optimized
solution is commercially available for treating bifurcation lesions. As
a result, cardiologists are forced to use a provisional strategy which
avoids the deployment of a second stent– leaving the un-stented side
branch vulnerable to thrombosis and restenosis. The ability to
definitively treat bifurcation lesions will enable PCI-stenting to
become the new standard of care for the treatment of left main coronary
artery disease rather than bypass surgery.
Tryton Medical’s Side-Branch Stent™ has all the characteristics of a
state-of the art workhorse stent, providing proven stent coverage to
bifurcation lesions while eliminating the need for provisional stenting.
For more information on Tryton Medical, Inc. For more information on
Tryton Medical, Inc., contact Joe Romano, Partner, HighGround, Inc. at
+1 781-279-1320 x 208, jromano@highgroundinc.com
or visit trytonmedical.com.